Bookmark

Add to MyYahoo RSS

Cubist Pharmaceuticals News

News on Cubist Pharmaceuticals (Ticker: CBST) continually updated from thousands of sources around the net.

11 hrs ago | BioSpace

Cubist Pharmaceuticals, Inc. To Present At August Investor Conference

Cubist Pharmaceuticals, Inc. today announced that company management will discuss Cubist's business activities and financial outlook at investor conferences during August 2013.

Comment?

Related Topix: Cubist Pharmaceuticals, Biotech, Medicine, Healthcare Industry

Thu Jul 24, 2014

BioSpace

Cubist Pharmaceuticals, Inc. Strikes Agreement With Competitor To Delay Generic Cubicin

A competitor of antibiotics maker Cubist Pharmaceuticals has agreed not to launch a generic version of its flagship drug for skin infections until at least Dec. 1 while a judge decides on a patent challenge.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Wed Jul 23, 2014

Theflyonthewall.com

National Oilwell downgraded to Accumulate from Buy at Tudor Pickering

On The Fly: Analyst Downgrade Summary Today's noteworthy downgrades include: 21st Century Fox downgraded to Market Perform from Outperform at Cowen... Brinker downgraded to Sector Perform from Outperform at RBC Capital... Cubist downgraded to Market Perform from Outperform at JMP Securities... DiamondRock downgraded to Neutral from Outperform at RW ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Banking, FirstMerit, Financial Services, Startups, Helmerich & Payne, Mcdonalds, Restaurant Management

Tue Jul 22, 2014

Seeking Alpha

Cubist Pharmaceuticals' (CBST) CEO Michael Bonney on Q2 2014 Results - Earnings Call Transcript

Good day. My name is Brenan, and I will be your event manager today. At this time, I'I like to welcome everyone to the Cubist Pharmaceutical Second Quarter Earnings Conference Call and Webcast.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals, Healthcare Law, Law, MRSA, Health

Freshnews

Cubist Reports Second Quarter 2014 Financial Results

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2014.

Comment?

Related Topix: Cubist Pharmaceuticals, Biotech, Medicine, Healthcare Industry, Food and Drug Administration, Centers for Disease Control and Prevention, E. Coli

Fri Jul 18, 2014

Business Journal

Cubist holds first ever volunteer day at charities around Boston

Micheal Bonney, CEO of Cubist Pharmaceuticals, slices zucchini at Pine Street Inn during the company's first-ever Cubes Who Care service day.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals, Life, Charity , Food, Vegetables

Business Journal

Cubist holds first ever volunteer day at charities around Boston

For Micheal Bonney and the 26 other employees of Cubist Pharmaceuticals who spent Friday morning slicing vegetables at Pine Street Inn, it was the onions that were the killer.

Comment?

Related Topix: Life, Charity , Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals, Food, Vegetables

Thu Jul 17, 2014

US Pharmacist

Update on the Management of Pediatric Acute Otitis Media

Costanzo have nothing to disclose. are the most common bacterial cause, other organisms including viruses can cause AOM.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Family Practice, Amoxicillin (generic), Amoxil, Trimox, Inflammation, Health, Influenza

Tue Jul 15, 2014

Freshnews

Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D....

EPIRUS Biopharmaceuticals, Inc. , a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will serve on its board of directors.

Comment?

Related Topix: Biotech, CombinatoRx, Medicine, Healthcare Industry, Sport Movies, Drama Movies, Comedy Movies, College, Sepracor, Food, J and J Snack Foods

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Mr. Venkitachalam joins PeopleFluent from Caradigm. )--Increased catastrophe and weather-related claims led to an increase in losses for the U.S. property/casualty industry in the first quarter of 2014, causing underwrit... )--Airclic, the leading provider of cloud-based solutions that enhance visibility and control throughout the mobile supply ... (more)

Comment?

Related Topix: Product Management, Biotech, Medicine, Healthcare Industry

Mon Jul 14, 2014

BioSpace

Achaogen Appoints As Chief Medical Officer

Achaogen, Inc. , a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant gram-negative infections, today announced the appointment of Ian Friedland, M.D. as its Chief Medical Officer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals, Pharmacology, World News, South Africa,

Tue Jul 01, 2014

BayStreet.ca

Cidara Therapeutics - "Back to the Rodeo"

New York, NY / ACCESSWIRE / July 1, 2014 / Cidara Therapeutics today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, Dr. Jeff Stein.

Comment?

Related Topix: Biotech, Cubist Pharmaceuticals, Medicine, Healthcare Industry

Mon Jun 30, 2014

Freshnews

Cidara Therapeutics Completes $32 Million Series A Financing

SAN DIEGO, Calif. -- -- Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak targeted immunotherapy platform and biafungin, a novel long acting echinocandin antifungal drug, into human ... (more)

Comment?

Related Topix: Venture Capital, Emerging Technology, Harvard University, Biotech, Cubist Pharmaceuticals, Medicine, Healthcare Industry, Infectious Diseases

Sun Jun 29, 2014

Seeking Alpha

Cepheid Developing A Rapid Diagnostic Test For Multidrug-Resistant Superbugs

In late January, I recommended that investors buy the molecular diagnostics company Cepheid just below $47, with 25% near term upside.

Comment?

Related Topix: Startups, Cepheid, Infectious Diseases, Medicine, Biotech, GlaxoSmithKline, AstraZeneca Group, Cubist Pharmaceuticals, Healthcare Industry

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••